The long-term goal of this project is to elucidate the mechanism of action and physiologic function of heparin cofactor H (HCII). HCII is an inhibitor of thrombin that is present in plasma at a concentration of -1 uM. The anticoagulant activity of HCII is greatly increased by heparin or dermatan sulfate, and dermatan sulfate proteoglycans on the surface of fibroblasts and smooth muscle cells stimulate HCH. Previously, cDNA and genomic clones for human and murine HCII were isolated, recombinant HCII was expressed in E. coli, site-directed mutagenesis was performed to identify important amino acid residues that interact with thrombin and glycosaminoglycans, and the structure of a high-affinity hexasaccharide that binds HCII in porcine skin dermatan sulfate was identified. Although the function of HCII in vivo remains unknown, indirect evidence suggests that HCII activity increases during pregnancy and perhaps serves to inhibit coagulation of maternal blood in the placenta. In addition, the presence of HCII in the intima of normal human arteries and the altered composition of dermatan sulfate (with reduced HCII-stimulating activity) in atherosclerotic lesions provide circumstantial evidence of a role for HCII in atherogenesis. By means of targeted gene disruption in embryonic stem cells, a murine model of HCII deficiency has been developed. The following specific aims are proposed: (1) Determine the effects of HCII deficiency on hemostasis, atherogenesis, wound repair, and inflammation in the mouse. (2) Determine the location of endogenous HCH in human and murine tissues by immunohistochemical methods and identify binding Sites for exogenous HCII in tissue sections. (3) Characterize the oligosaccharide structures in glycosaminoglycans derived from placenta and other tissues that are required for interaction with HCII. (4) Determine the prevalence of HCII deficiency in patients with atherosclerosis. New information about the structure, mechanism of action, and function of HCII in vivo will provide a better understanding of the regulation of thrombin activity under normal and pathologic conditions.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL055520-06A2
Application #
6543596
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Link, Rebecca P
Project Start
1996-05-01
Project End
2006-06-30
Budget Start
2002-08-01
Budget End
2003-06-30
Support Year
6
Fiscal Year
2002
Total Cost
$379,481
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Myerson, Jacob Wheatley; He, Li; Allen, John Stacy et al. (2014) Thrombin-inhibiting nanoparticles rapidly constitute versatile and detectable anticlotting surfaces. Nanotechnology 25:395101
Kalle, Martina; Papareddy, Praveen; Kasetty, Gopinath et al. (2013) Proteolytic activation transforms heparin cofactor II into a host defense molecule. J Immunol 190:6303-10
Vicente, Cristina P; Weiler, Hartmut; Di Cera, Enrico et al. (2012) Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis. Thromb Res 130:646-8
Charles, Julia F; Coury, Fabienne; Sulyanto, Rosalyn et al. (2012) The collection of NFATc1-dependent transcripts in the osteoclast includes numerous genes non-essential to physiologic bone resorption. Bone 51:902-12
Godoy, Juliana A P; Block, Daniel B; Tollefsen, Douglas M et al. (2011) Dermatan sulfate and bone marrow mononuclear cells used as a new therapeutic strategy after arterial injury in mice. Cytotherapy 13:695-704
Riehl, T E; He, L; Zheng, L et al. (2011) COX-1(+/-)COX-2(-/-) genotype in mice is associated with shortened time to carotid artery occlusion through increased PAI-1. J Thromb Haemost 9:350-60
Sarilla, Suryakala; Habib, Sally Y; Tollefsen, Douglas M et al. (2010) Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli. Anal Biochem 406:166-75
Werneck, Claudio C; Vicente, Cristina P; Weinberg, Justin S et al. (2008) Mice lacking the extracellular matrix protein MAGP1 display delayed thrombotic occlusion following vessel injury. Blood 111:4137-44
He, Li; Giri, Tusar K; Vicente, Cristina P et al. (2008) Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II. Blood 111:4118-25
Vicente, Cristina P; He, Li; Tollefsen, Douglas M (2007) Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood 110:4261-7

Showing the most recent 10 out of 27 publications